Gain Therapeutics, Inc. (NASDAQ:GANX) Shares Purchased by Northern Trust Corp

Northern Trust Corp lifted its position in shares of Gain Therapeutics, Inc. (NASDAQ:GANX) by 88.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 84,586 shares of the company’s stock after purchasing an additional 39,642 shares during the period. Northern Trust Corp owned about 0.32% of Gain Therapeutics worth $183,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in the business. Benedict Financial Advisors Inc. bought a new position in Gain Therapeutics in the 4th quarter worth approximately $35,000. Sprott Inc. acquired a new stake in shares of Gain Therapeutics in the fourth quarter worth $30,000. Jones Financial Companies Lllp boosted its holdings in Gain Therapeutics by 83.6% in the 4th quarter. Jones Financial Companies Lllp now owns 98,250 shares of the company’s stock valued at $212,000 after purchasing an additional 44,750 shares during the period. Finally, Marshall Wace LLP acquired a new position in shares of Gain Therapeutics in the fourth quarter valued at $198,000. 11.97% of the stock is owned by institutional investors and hedge funds.

Gain Therapeutics Price Performance

Shares of GANX stock opened at $1.93 on Tuesday. The company has a quick ratio of 2.99, a current ratio of 2.99 and a debt-to-equity ratio of 0.04. The company has a market cap of $57.05 million, a P/E ratio of -1.75 and a beta of 0.17. Gain Therapeutics, Inc. has a twelve month low of $0.89 and a twelve month high of $3.19. The business has a fifty day simple moving average of $1.84 and a 200 day simple moving average of $1.99.

Gain Therapeutics (NASDAQ:GANX) last issued its earnings results on Wednesday, May 14th. The company reported ($0.16) EPS for the quarter, meeting analysts’ consensus estimates of ($0.16). On average, sell-side analysts forecast that Gain Therapeutics, Inc. will post -1 EPS for the current fiscal year.

Analyst Ratings Changes

GANX has been the topic of several research analyst reports. Chardan Capital reissued a “buy” rating and set a $6.00 price target on shares of Gain Therapeutics in a research note on Friday, March 28th. HC Wainwright reaffirmed a “buy” rating and set a $8.00 price target on shares of Gain Therapeutics in a research report on Monday, May 19th. Finally, Scotiabank started coverage on Gain Therapeutics in a report on Friday, March 7th. They set a “sector outperform” rating and a $12.00 price objective for the company. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Gain Therapeutics currently has an average rating of “Buy” and an average price target of $8.20.

Gain Therapeutics Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.